Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Arthritis and Rheumatism
|
February 1, 2011
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry
Bente Glintborg, Mikkel Østergaard, Lene Dreyer, et al.
Annals of the Rheumatic Diseases
|
June 8, 2010
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
William G Dixon, Loreto Carmona, Axel Finckh, et al.
Rheumatology International
|
January 20, 2011
Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naïve rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment
Trine Bay Laurberg, Torkell Ellingsen, Jonas Thorsen, et al.
Rheumatology (Oxford, England)
|
December 26, 2016
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis
Simon Tarp, Daniel Eric Furst, Maarten Boers, et al.
Annals of the Rheumatic Diseases
|
May 10, 2011
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
Henrik Christian Leffers, Mikkel Ostergaard, Bente Glintborg, et al.
The Journal of Rheumatology
|
August 18, 2009
Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls
Trine Bay Laurberg, Jan Frystyk, Torkell Ellingsen, et al.
Arthritis Care & Research
|
May 17, 2017
Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial
Annette de Thurah, Kristian Stengaard-Pedersen, Mette Axelsen, et al.
Arthritis and Rheumatism
|
March 6, 2013
Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry
Bente Glintborg, Mikkel Ostergaard, Niels Steen Krogh, et al.
Annals of the Rheumatic Diseases
|
March 29, 2007
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Elisabeth Hjardem, Mikkel Østergaard, Jan Pødenphant, et al.
Arthritis and Rheumatism
|
December 30, 2009
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Arthritis and Rheumatism
|
February 1, 2011
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry
Bente Glintborg, Mikkel Østergaard, Lene Dreyer, et al.
Annals of the Rheumatic Diseases
|
June 8, 2010
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
William G Dixon, Loreto Carmona, Axel Finckh, et al.
Rheumatology International
|
January 20, 2011
Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naïve rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment
Trine Bay Laurberg, Torkell Ellingsen, Jonas Thorsen, et al.
Rheumatology (Oxford, England)
|
December 26, 2016
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis
Simon Tarp, Daniel Eric Furst, Maarten Boers, et al.
Annals of the Rheumatic Diseases
|
May 10, 2011
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
Henrik Christian Leffers, Mikkel Ostergaard, Bente Glintborg, et al.
The Journal of Rheumatology
|
August 18, 2009
Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls
Trine Bay Laurberg, Jan Frystyk, Torkell Ellingsen, et al.
Arthritis Care & Research
|
May 17, 2017
Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial
Annette de Thurah, Kristian Stengaard-Pedersen, Mette Axelsen, et al.
Arthritis and Rheumatism
|
March 6, 2013
Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry
Bente Glintborg, Mikkel Ostergaard, Niels Steen Krogh, et al.
Annals of the Rheumatic Diseases
|
March 29, 2007
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Elisabeth Hjardem, Mikkel Østergaard, Jan Pødenphant, et al.
Arthritis and Rheumatism
|
December 30, 2009
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp, et al.
Page
of 4